Perspective: How will healthcare reform affect cancer care?

Article

In this video interview, Oncology board member and CancerNetwork contributing editor, Derek Raghavan, MD, PhD, Institute Chair, Taussig Cancer Institute gives his opinion on how the changing landscape of the American healthcare system will affect cancer care.

In this video interview, Oncology board member and CancerNetwork contributing editor, Derek Raghavan, M.D., Ph.D, Institute Chair, Taussig Cancer Institute gives his opinion on how the changing landscape of the American healthcare system will affect cancer care.

Interview: news.cancerconnect.com/asco-2010-how-will-healthcare-reform-affect-cancer-care/

Perspectives and concerns about the affects of Obama-care abound…

On July, 14th the Community Oncology Alliance (COA) announced that due to severe year after year cuts to Medicare reimbursement for cancer care, community oncologists around the US are closing offices at a rate rapidly increasing since January 2010. Reductions in staff, services and facilities are also on the rise.

“As a practicing oncologist, I am extremely concerned about the impact these closings have on
patients. Many are simply falling through the cracks as providers are being forced to cut staff and
close clinics, forcing patients to seek treatments outside of their communities,” said David Eagle,
MD, newly elected President of COA.

--Look here for continuing coverage and analysis of the policies coming from Capitol Hill that directly impact the delivery of oncology services across the country.

 

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content